

ALZHEIMER'S DISEASE DRUG DEVELOPMENT PIPELINE: 2023

The 2023 pipeline shows progress and provides hope for greater success in Alzheimer's disease treatment



In 2023, there are

141 UNIQUE THERAPIES in **187** CLINICAL TRIALS for Alzheimer's disease as registered on **clinicaltrials.gov**

58 new agents have entered the pipeline in the past year

Therapies in the pipeline

44% of disease-modifying treatments (DMTs) are biologics (an increase from previous years), possibly reflecting the success of monoclonal antibodies

56% of DMTs are small molecules

28% of candidate therapies are repurposed from other diseases



The total number of participants needed to populate all currently active trials (Phases 1, 2 and 3) is

57,465

Targets of agents currently in clinical trials include



78% disease modification

11% cognitive enhancement

11% behavioral and neuropsychiatric symptoms

Agents with primary mechanistic targets include



72% novel disease processes

28% amyloid and tau

Inflammation and synaptic plasticity are the most well represented novel themes in the pipeline

PHASE 3 CLINICAL TRIALS



36 agents



55 trials

PHASE 2 CLINICAL TRIALS



87 agents



99 trials

PHASE 1 CLINICAL TRIALS



31 agents



33 trials



Across all trials

sponsored

58%

by the biopharma industry

32%

by Academic Medical Centers (with funding from NIH, industry, the Alzheimer's Association, and other entities)

9%

by public-private partnerships

1%

by other entities